Last reviewed · How we verify

NCT03739801

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Withdrawn Phase 1, PHASE2 Last updated 27 March 2020
What this trial tests

Phase 1, PHASE2 trial testing Liposomal Irinotecan in Locally Advanced Unresectable Gastric Adenocarcinoma. Withdrawn.

Timeline
6 April 2020
Primary endpoint
6 April 2022
6 April 2023

Quick facts

Lead sponsorUniversity of Southern California
PhasePhase 1, PHASE2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date6 April 2020
Primary completion6 April 2022
Estimated completion6 April 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Locally Advanced Unresectable Gastric Adenocarcinoma or Metastatic Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects and best dose of MM-398 and ramucirumab in treating patients with gastric cancer or gastroesophageal junction adenocarcinoma. MM-398 contains a chemotherapy drug called irinotecan, which in its active form interrupts cell reproduction. MM-398 builds irinotecan into a container called a liposome which may be able to release the medicine slowly over time to reduce side effects and increase its ability to kill tumor cells. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving MM-398 and ramucirumab together may work better in treating patients with gastric cancer or gastroesophageal junction adenocarcinoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.
    Liang BJ, Pigula M, Baglo Y, Najafali D, et al · · 2020 · cited 82× · PMID 31898555 · DOI 10.1186/s12951-019-0560-5
  2. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials.
    Lenders V, Koutsoumpou X, Sargsian A, Manshian BB. · · 2020 · cited 59× · PMID 36132021 · DOI 10.1039/d0na00478b
  3. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.
    Yu S, Wang Y, He P, Shao B, et al · · 2022 · cited 59× · PMID 35198442 · DOI 10.3389/fonc.2022.809304
  4. Nanoparticles in Gastrooncology.
    Jefremow A, Neurath MF. · · 2020 · cited 5× · PMID 32355665 · DOI 10.1159/000506908
  5. Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics.
    Ultimo A, Jain A, Gomez-Gonzalez E, Alex TS, et al · · 2025 · cited 1× · PMID 40184281 · DOI 10.1021/acs.molpharmaceut.4c00822

Verify or expand the search:

Other trials of Liposomal Irinotecan

Trials testing the same drug.

Other recruiting trials for Locally Advanced Unresectable Gastric Adenocarcinoma

Currently open trials in the same condition.

Other University of Southern California trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739801.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing